PLCB2-AS1

Across TCGA pan-cancer cohorts, PLCB2-AS1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PLCB2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PLCB2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PLCB2-AS1 is over-expressed in tumor, although a few such as PAAD and UCEC show the opposite, repressed pattern.

KIRC, HNSC, and PAAD are the cancer types where PLCB2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLCB2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.073	<.001	8	view →
HNSC	All	II,III,IV	+0.061	.009	4	view →
PAAD	Male	All	−0.380	.010	2	view →
STAD	All	All	+0.088	.034	2	view →
UCEC	All	All	−0.042	.044	2	view →
LUAD	All	All	+0.107	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PLCB2-AS1–KIRC

Open the KIRC breakdown →